Search results
PROMOTED
Author(s):
Nicolas M Van Mieghem
,
Kendra J Grubb
,
David Hildick-Smith
,
et al
Start date:
Mar 26, 2024
Author(s):
Paul Sorajja
Added:
10 months ago
EuroPCR 23 - Dr Paul Sorajja (Abbott Northwestern Hospital, US) joined us to discuss the TRILUMINATE Pivotal study (NCT03904147).
The aim of this trial is to evaluate the safety and effectiveness of the tricuspid transcatheter edge-to-edge repair (TriClip, Abbott) in improving clinical outcomes for symptomatic patients with severe tricuspid regurgitation (TR) who have an intermediate or higher…
View more
Author(s):
Frederik Zimmermann
Added:
1 year ago
In this late-breaking interview from ACC.22, Dr Frederik Zimmermann (Catharina Hospital, NL) outlines the main findings of the FAME 3 Trial.
FAME 3 is an international, randomised multicentre trial, that aims to compare the outcomes of fractional flow reserve (FFR)-guided PCI and Coronary Artery Bypass Graft Surgery (CABG) in patients with multivessel coronary artery disease. The results…
View more
Cardiovascular Research Foundation
Supplier
Mauro Lencioni
Job title: Consultant Cardiologist & Electrophysiologist
Author
Author(s):
David J Cohen
Added:
2 years ago
Dr David J Cohen (St Francis Hospital, Roslyn, NY, US) discusses the findings from PARTNER 3 Economic Study. The study, presented first at TCT 2021, showed that for patients with severe AS and low surgical risk, TF-TAVR with the SAPIEN 3 valve is cost-saving compared with SAVR at 2-year follow-up.
Discussion Points
Importance of the Study
Used Data
Complexities in Relation to the Costs of…
View more
Sarah Godfrey
Job title: Cardiovascular Disease and Hospice & Palliative Medicine Fellow
Author
Editorial
Author(s):
Angela Hoye
Added:
3 years ago
Article
Author(s):
Nicolas M Van Mieghem
Added:
5 years ago
An analysis of the late-breaking trials from ACC 2019 presented by Dr Nicolas van Mieghem (Erasmus MC, Rotterdam, NL).
Filmed on site at ACC 2019 by Radcliffe Cardiology
Topics:
00:19 - Apple Heart Study
01:50 - PARTNER 3 Trial
03:44 - CoreValve Low Risk Study
06:26 - STS/TVT Registry Sub-Analysis
07:32 - COAPT Quality of Life Analysis
07:43 - COAPT Echo Sub-Analysis
08:14 - AUGUSTUS…
View more